JW Pharmaceutical Corporation(KR:001060)
â‚©23,600.00+50.00 (+0.21%)
KR:001060
JW Pharmaceutical Corporation financials statements
â‚©23,600.00
At close:+50.00 (+0.21%)
Want to see KR:001060 full AI Analyst Report?
JW Pharmaceutical Corporation (001060) Ratios
JW Pharmaceutical Corporation Ratios
KR:001060's free cash flow for Q2 2026 was ₩40.19B. For the 2026 fiscal year, KR:001060's free cash flow was decreased by ₩-2.32B and operating cash flow was ₩42.51B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.42 | 1.47 | 1.32 | 1.12 | 1.30 |
| Quick Ratio | 0.89 | 0.93 | 0.95 | 0.83 | 0.93 |
| Cash Ratio | 0.19 | 0.05 | 0.06 | 0.09 | 0.12 |
| Solvency Ratio | 0.34 | 0.31 | 0.16 | 0.12 | 0.03 |
| Operating Cash Flow Ratio | 0.46 | 0.38 | 0.30 | 0.15 | 0.06 |
| Short-Term Operating Cash Flow Coverage | 3.00 | 1.92 | 0.77 | 0.27 | 0.15 |
| Net Current Asset Value | â‚© 60.61B | â‚© 31.30B | â‚© -1.51B | â‚© 23.24B | â‚© -78.06B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.09 | 0.15 | 0.26 | 0.33 | 0.39 |
| Debt-to-Equity Ratio | 0.15 | 0.28 | 0.64 | 0.87 | 1.22 |
| Debt-to-Capital Ratio | 0.13 | 0.22 | 0.39 | 0.47 | 0.55 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.07 | 0.10 | 0.01 | 0.38 |
| Financial Leverage Ratio | 1.64 | 1.83 | 2.43 | 2.61 | 3.15 |
| Debt Service Coverage Ratio | 2.17 | 1.80 | 0.58 | 0.27 | 0.18 |
| Interest Coverage Ratio | 19.86 | 8.22 | 7.69 | 6.71 | 4.25 |
| Debt to Market Cap | 0.05 | 0.12 | 0.17 | 0.50 | 0.48 |
| Interest Debt Per Share | 2446.29 | 4362.64 | 7431.10 | 9151.79 | 10879.07 |
| Net Debt to EBITDA | 0.14 | 0.74 | 1.73 | 2.39 | 4.69 |
| Profitability Margins | |||||
| Gross Profit Margin | 46.38% | 44.97% | 44.84% | 42.08% | 38.64% |
| EBIT Margin | 11.34% | 12.66% | 8.92% | 8.22% | 4.78% |
| EBITDA Margin | 13.76% | 15.31% | 11.92% | 10.73% | 7.44% |
| Operating Profit Margin | 11.34% | 11.47% | 12.91% | 9.20% | 5.14% |
| Pretax Profit Margin | 11.47% | 11.46% | 7.33% | 6.63% | 3.38% |
| Net Profit Margin | 7.96% | 9.04% | 4.94% | 4.66% | -0.15% |
| Continuous Operations Profit Margin | 7.96% | 9.04% | 5.13% | 4.36% | -0.24% |
| Net Income Per EBT | 69.44% | 78.91% | 67.48% | 70.30% | -4.48% |
| EBT Per EBIT | 101.09% | 99.92% | 56.75% | 72.05% | 65.81% |
| Return on Assets (ROA) | 10.19% | 10.76% | 5.74% | 5.08% | -0.15% |
| Return on Equity (ROE) | 16.70% | 19.74% | 13.94% | 13.27% | -0.46% |
| Return on Capital Employed (ROCE) | 22.18% | 20.83% | 26.98% | 25.40% | 8.90% |
| Return on Invested Capital (ROIC) | 14.08% | 14.74% | 14.24% | 9.10% | -0.46% |
| Return on Tangible Assets | 11.41% | 11.54% | 6.02% | 5.21% | -0.15% |
| Earnings Yield | 10.02% | 11.62% | 4.33% | 7.61% | -0.18% |
| Efficiency Ratios | |||||
| Receivables Turnover | 6.55 | 4.62 | 4.31 | 4.64 | 3.23 |
| Payables Turnover | 7.45 | 6.64 | 5.59 | 4.78 | 7.21 |
| Inventory Turnover | 3.79 | 3.54 | 3.89 | 3.55 | 3.63 |
| Fixed Asset Turnover | 4.69 | 4.18 | 4.81 | 5.56 | 5.12 |
| Asset Turnover | 1.28 | 1.19 | 1.16 | 1.09 | 0.96 |
| Working Capital Turnover Ratio | 8.37 | 7.61 | 10.97 | 10.60 | 8.18 |
| Cash Conversion Cycle | 103.10 | 127.09 | 113.17 | 105.16 | 162.80 |
| Days of Sales Outstanding | 55.69 | 79.03 | 84.67 | 78.68 | 112.90 |
| Days of Inventory Outstanding | 96.43 | 103.02 | 93.79 | 102.82 | 100.54 |
| Days of Payables Outstanding | 49.02 | 54.96 | 65.29 | 76.34 | 50.64 |
| Operating Cycle | 152.12 | 182.05 | 178.46 | 181.51 | 213.44 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 3992.89 | 3403.72 | 3542.26 | 2372.90 | 780.94 |
| Free Cash Flow Per Share | 3505.28 | 2197.40 | 1887.91 | 1856.53 | 225.03 |
| Dividend Paid and CapEx Coverage Ratio | 4.22 | 2.10 | 1.76 | 2.88 | 0.90 |
| Capital Expenditure Coverage Ratio | 8.19 | 2.82 | 2.14 | 4.60 | 1.40 |
| Operating Cash Flow Coverage Ratio | 1.76 | 0.87 | 0.51 | 0.27 | 0.07 |
| Operating Cash Flow to Sales Ratio | 0.12 | 0.11 | 0.12 | 0.08 | 0.03 |
| Free Cash Flow Yield | 13.75% | 9.16% | 5.43% | 10.60% | 1.04% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 10.06 | 9.08 | 23.10 | 13.14 | -547.94 |
| Price-to-Sales (P/S) Ratio | 0.79 | 0.78 | 1.14 | 0.61 | 0.83 |
| Price-to-Book (P/B) Ratio | 1.67 | 1.70 | 3.22 | 1.74 | 2.50 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 7.27 | 10.92 | 18.41 | 9.43 | 96.44 |
| Price-to-Operating Cash Flow Ratio | 6.39 | 7.05 | 9.81 | 7.38 | 27.79 |
| Price-to-Earnings Growth (PEG) Ratio | -2.42 | 0.11 | 1.84 | -0.00 | 5.85 |
| Enterprise Value Multiple | 5.92 | 5.82 | 11.31 | 8.09 | 15.85 |
| Enterprise Value | 631.02B | 641.10B | 1.01T | 594.61B | 715.43B |
| EV to EBITDA | 5.92 | 5.82 | 11.31 | 8.09 | 15.85 |
| EV to Sales | 0.81 | 0.89 | 1.35 | 0.87 | 1.18 |
| EV to Free Cash Flow | 7.46 | 12.51 | 21.73 | 13.39 | 136.99 |
| EV to Operating Cash Flow | 6.55 | 8.08 | 11.58 | 10.48 | 39.47 |
| Tangible Book Value Per Share | 12629.94 | 12375.14 | 9554.32 | 8757.33 | 7198.66 |
| Shareholders’ Equity Per Share | 15299.88 | 14125.91 | 10788.07 | 10047.41 | 8669.20 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.31 | 0.21 | 0.30 | 0.34 | 1.07 |
| Revenue Per Share | 32093.48 | 30841.40 | 30421.73 | 28607.60 | 26136.89 |
| Net Income Per Share | 2555.25 | 2788.43 | 1504.02 | 1333.15 | -39.61 |
| Tax Burden | 0.69 | 0.79 | 0.67 | 0.70 | -0.04 |
| Interest Burden | 1.01 | 0.91 | 0.82 | 0.81 | 0.71 |
| Research & Development to Revenue | 0.06 | 0.05 | 0.04 | 0.05 | 0.03 |
| SG&A to Revenue | 0.22 | 0.22 | 0.20 | 0.19 | 0.19 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.65 | 1.22 | 2.48 | 1.90 | -12.57 |
Currency in KRW
